Abstract: Proposed origins of pelvic serous carcinoma include the ovary, fallopian tube, and peritoneum. Prophylactic salpingo-oophorectomies in BRCA+ women have recently identified the fimbria as a site of origin for early serous carcinoma (tubal intraepithelial carcinoma or TIC). We explored the relationship of TIC to pelvic serous carcinomas in consecutive cases with complete adnexal exam (SEE-FIM protocol). Cases positive (group A) or negative (group B) for endosalpinx (including fimbria) involvement, were subclassified as tubal, ovarian, or primary peritoneal in origin. Coexisting TIC was recorded in group A when present and p53 mutation status was determined in 5 cases. Of 55 evaluable cases, 41 (75%) were in group A; including tubal (n = 5), peritoneal (n = 6), and ovarian (n = 30) carcinomas. Foci of TIC were identified in 5 of 5, 4 of 6, and 20 of 30, respectively. Ninetythree percent of TICs involved the fimbriae. Five of 5 TICs and concurrent ovarian carcinomas contained identical p53 mutations. Thirteen of 14 cases in group B were classified as primary ovarian carcinomas, 10 with features supporting an origin in the ovary. Overall, 71% and 48% of ''ovarian'' serous carcinomas had endosalpinx involvement or TIC. TIC coexists with all forms of pelvic serous carcinoma and is a plausible origin for many of these tumors. Further studies are needed to elucidate the etiologic significance of TIC in pelvic serous carcinoma, reevaluate the criteria for tubal, peritoneal, and ovarian serous carcinoma, and define the role of the distal tube in pelvic serous carcinogenesis.
O
varian cancer is diagnosed in approximately 25,000 women yearly in the United States, accounting for approximately 12,500 deaths. 22 It can be divided into 2 general histopathologic categories, each of which can be distinguished by its molecular pathogenesis and propensity for extraovarian spread. The first consists of tumors of borderline malignancy, low-grade serous carcinomas, endometrioid, and mucinous ovarian carcinomas. These tumors predominate in the ovarian parenchyma, are often confined to one or more cysts (intracystic) and do not typically originate from, or involve, the ovarian surface. The pathogenesis of this first type involves multiple biologic events paralleling a histologic progression from benign to malignant. These include microsatellite instability and mutations in KRAS, BRAF, b-catenin, and pTEN. 26 The second group consists of serous carcinomas, which have 3 proposed origins, including the ovarian surface epithelium or mullerian inclusions, fallopian tube mucosa, and mullerian epithelium elsewhere in the peritoneal cavity. 12 The pathogenesis of this second group frequently involves mutations in the p53 tumor suppressor gene and typically involves a rapid evolution, often in the absence of a preexisting benign precursor condition. 26 Because of their propensity for serosal organ involvement and rapid peritoneal spread, serous carcinomas are the most lethal form of pelvic epithelial cancer. 6 Fallopian tube serous carcinomas originate, by definition, from neoplastic transformation of the salpingeal mucosa (tubal intraepithelial carcinoma or TIC), which must be present to designate the tube as the primary tumor site. In contrast, intraepithelial carcinoma is rarely identified within ovarian or peritoneal carcinomas and coexisting TIC is likewise considered rare. 2, 4, 25 Thus, pathologists usually designate a serous tumor as ovarian or peritoneal based on the extent to which these organs are involved and after other sources are excluded (Table 1) .
Recently, studies of prophylactic salpingo-oophorectomies in women with BRCA mutations (BRCA+) have identified the fallopian tube as a frequent source of early serous carcinoma, occurring in up to 100% of cases in which early malignancy is discovered. 11, 13, 21 Many of these tumors are still confined to the mucosal surface in the form of TIC. Using protocols for examining the entire fallopian tube, we and others have shown that the majority of these tumors are localized to the fimbrial end of the tube, in both BRCA-positive and BRCAnegative women. 1, 8, 18 BRCA mutations confer an increased risk of all forms of pelvic serous carcinoma. 30 In view of the recent discovery that the distal tube is an important early site of tumor involvement, we addressed the hypothesis that TIC contributes to pelvic serous carcinomas in unselected populations. This study summarizes our recent experience with a consecutive series of serous ovarian cancers in which the entire fallopian tubes were sectioned and examined for the presence of TIC. 
METHODS

Case Selection
Examination of the Ovaries
The histologic diagnosis was verified or revised after pathologic review. 15 The presence or absence of ovarian involvement, the extent of involvement, and the presence or absence of surface involvement were recorded. The latter was characterized by tumor visibly on the surface, or within adhesions. In addition to the distribution of the tumor, coexisting ovarian conditions, such as endometriosis, cystadenomas, and adenofibromas, were also noted when present.
Examination of Fallopian Tubes
In each case in which the fallopian tubes could be identified, the tubes were entirely sectioned using a protocol designed to section and extensively examine the fimbriae (SEE-FIM protocol). 9, 18 This protocol entailed amputation of each fimbria at the infundibulum, longitudinal sectioning of the fimbria, and extensive cross sectioning of the remainder of the tube at 2-mm intervals. In all cases where the tubes were identified, the entire fallopian tube(s) was submitted for evaluation. All sections were reviewed and cases were classified as follows: group A demonstrated involvement of the mucosa or submucosa of the inner lining of the tube. Group A was further subdivided into those with and without TIC. Group B consisted of tumors that did not involve the tubes, or involved the tubal serosa only.
Diagnosis of TIC
Two coauthors (C.P.C. and D.K.) screened all cases concurrently. A diagnosis of TIC was made by consensus agreement. In selected cases, p53 immunostaining was performed to illustrate the histologic transitions from normal to TIC, as previously described. 18 The histologic criteria for TIC were based on prior studies of early intraepithelial carcinomas of the fallopian tube in BRCA (+) women, similar descriptions of intraepithelial serous carcinomas in the tube and endometrium and criteria from the World Health Organization.
2,10,18,31 TIC was distinguished from normal mucosa by a variably stratified epithelium (1 to 6 layers) with nuclear enlargement, prominent nucleoli, variable loss of cell polarity and mitotic activity (Fig. 1A, arrowheads) . These features were identical to those seen in TIC in prophylactic specimens from BRCA+ women (Fig. 1B, arrow  heads) . 18 Previous reports have also shown these epithelia to be intensely p53 immunopositive, similar to serous carcinoma. 8, 18 Case Classification
In addition to the above, each case was classified as a presumptive ovarian, tubal, or peritoneal serous carcinoma based on the criteria outlined in Table 1 . 5, 15 This classification was applied by the coauthors (D.K. and C.P.C.) on review of each case, irrespective of the original diagnosis and was based on both review of the gross description from the pathology report and histology. Cases in which the bulk of the neoplasm was identified in the tube, demonstrated a transition from normal to TIC, and were not accompanied by endometrial cancer, were classified as primary tubal carcinomas. Cases with predominately peritoneal tumor and minimal ovarian surface or tubal involvement were classified as primary peritoneal carcinomas. Because fallopian tubes are not examined completely to exclude TIC in routine practice, and because TIC by itself does not exclude a diagnosis of ovarian and peritoneal serous carcinomas in current classification systems, the presence or absence of TIC alone did not preclude a diagnosis of primary ovarian or peritoneal carcinoma.
Analysis for p53 Mutations
Selected tissue blocks from cases of coexisting TIC and ovarian cancer were retrieved. Laser capture microdissection was used to isolate DNA from both TIC and concurrent ovarian cancer tissue using the PALM microbeam instrument. Samples were incubated at 621C with proteinase K for 48 hours followed by the addition of Chelex (Biorad, Burlingame, CA) and boiling for 10 minutes. Genomic DNA was amplified by polymerase chain reaction (PCR), using tailed primers designed to amplify exons 2 to 9 and 11 of p53. A secondary amplification was performed using T3 and T7 primers specific to the tail sequence used in the primary amplification. PCR products were then sequenced from both strands using T3 and T7 primers. Data were analyzed using the Mutation Surveyor program (Soft Genetics, State College, PA). Candidate mutations found by the software were compared to a reference database for cancer-associated p53 mutations (Universal mutation database, http://www.umd.be:2072/IFAMTP53A.shtml). All PCR-amplification-sequence analyses were performed in duplicate to exclude potential artifacts in sequencing, as previously recommended. 28, 32 All PCR amplification and sequence analysis was performed by one of the coauthors (A.M.) on coded specimens and interpreted without knowledge of the tissue diagnosis.
RESULTS
Sixty-three consecutive cases of pelvic serous carcinoma were evaluated. Eight were excluded, either because both tubes were not available for review or because the slides from the case were not available. The remaining 55 are the subject of this analysis. Patients ranged from 43 to 82 years of age (mean: 61.5 y). Table 2 summarizes the findings in the cases studied. Of the 55 remaining cases, 41 (75%) demonstrated involvement of the inner lining of the fallopian tubes (group A). Eleven exhibited minimal or exclusively superficial ovarian involvement by tumor, and were classified as primary tubal (5) or peritoneal (6) according to the criteria in Table 1 . Three of the primary tubal carcinomas were derived from prophylactic salpingo-oophorectomies of BRCA+ women. Of the remaining 6, classified as primary peritoneal serous carcinomas, 4 exhibited TIC (Fig. 2 ). In the other two, partial replacement of the tubal mucosa was identified, but TIC was not confirmed. The remaining 30 cases were classified as primary ovarian carcinomas based on the location of the largest tumor mass. One reported a strong family history of breast and ovarian cancer in the pathology report. All but two exhibited both ovarian surface and parenchymal involvement with variable cyst formation. Two tumors were almost exclusively parenchymal. All but one involved both ovaries. TIC was identified in the fallopian tubes in 20 of 30 (67%).
TIC predominately involved the distal fallopian tube, involving the fimbriae in 27 of 29 cases (93%). In 2 cases (7%) TIC was present in both tubes. When positive, p53 immunostaining highlighted both intraepithelial and invasive components (Figs. 3A, B) . TIC exhibited variably stratified epithelium with nuclear atypia relative to the normal salpingeal mucosa (Figs. 3C, D) , often coexisting with stromal invasion (Figs. 3A, C) . The ovarian tumor typically involved the ovarian surface (Fig.  3E ) but also frequently the ovarian parenchyma (Fig. 4) . In 2 cases classified as ovarian carcinoma, salpingeal epithelium-interpreted as tubo-ovarian adhesions adjacent to the main tumor mass-demonstrated TIC in zPresence of a single, large, predominately intraparenchymal ovarian tumor mass (included one with an endometriotic cyst).
yEndometrial involvement was seen in 4 cases. All were interpreted as tumor implants rather than primary endometrial carcinoma, based on size and distribution.
NA, not applicable.
continuity with normal mucosa (Fig. 5) . One of the 41 cases in group A contained a concurrent benign ovarian endometriotic cyst. Two contained multiple small plaquelike deposits on the endometrial surface interpreted as ''drop metastases.'' One other contained a synchronous grade 1 endometrioid adenocarcinoma (Table 2 ). 
Kindelberger et al
Five cases originally classified as primary ovarian carcinomas that also included TIC were analyzed for p53 mutations. Laser-capture microdissected DNA from at least one TIC and ovarian tumor site in each case was sequenced. The results are summarized in Table 3 and each case is illustrated in Figure 4 . One polymorphism (c.215CG, p.P72R) was identified in both normal and abnormal epithelium in a portion of the cases studied. Excluding this polymorphism, identical mutations were identified in at least one focus of TIC and ovarian cancer in all 5 (Table 3) . In one case, a second focus of TIC displayed an additional mutation; in another, a different mutation was found, consistent with an independent origin. This is consistent with prior reports of multifocal TIC. 8 Fourteen cases did not demonstrate involvement of the inner mucosal surface of the tubes (group B). One presented as a solitary mass in the peritoneum, sparing both tubes and ovaries, and was classified as a primary peritoneal tumor. This tumor was associated with bilateral seromucinous cystadenomas, suggesting a possible role of endometriosis in the pathogenesis of this tumor. Of the remaining 13, which were classified as primary ovarian carcinomas, 9 were bilateral; 4 were associated with a single large predominately intraparenchymal ovarian mass, one of which was associated with an endometriotic cyst. Four were associated with an ovarian cystadenoma or adenofibromas, and one with a grade 1 serous carcinoma of the ovary. Two contained endometrial involvement characteristic of metastatic serous carcinoma (drop metastases).
DISCUSSION
The principal criteria for distinguishing ovarian, tubal, and primary peritoneal serous carcinomas are the tumor distribution and presence or absence of a precursor condition. The latter includes an intraepithelial carcinoma or a predisposing condition, such as an endometriotic cyst, cystadenoma or borderline tumor. Coexisting intraepithelial carcinoma is a prerequisite for a diagnosis of primary tubal carcinoma; however, it is rarely reported in serous carcinomas attributed to the ovary or peritoneum. 3, 4 Thus, pathologists classify ovarian and peritoneal serous carcinomas based on tumor distribution. Large ovarian tumors with parenchymal involvement are usually designated as ovarian and peritoneal tumors with little or no ovarian surface involvement and/or a dominant tubal mass are termed peritoneal primaries. Molecular studies suggest that these tumor subsets differ with respect to single (ovarian) or multiple (peritoneal) origins and low (peritoneal) versus high (ovarian) frequency of allelic imbalance. 7, 24, 29 However, because assignment of a primary site for a pelvic serous tumor is frequently made in the absence of a defined precursor lesion, the classification of these tumors, and the interpretation of sophisticated studies attempting to distinguish these groups, are subject to error. This is the first study to prospectively study the fallopian tubes in a consecutive series of pelvic serous carcinomas, and entailed complete examination of the fallopian tubes when they could be located, with special attention given to the fimbriated end (SEE-FIM protocol). We thoroughly examined the fimbriae because they are frequently involved in cases of early serous carcinoma discovered in BRCA(+) women and have emerged as a credible source for cancers arising in the fallopian tube, irrespective of family history. 8, 13, 18 Moreover, an increasing body of evidence has suggested that the fallopian tube plays a greater part in the pathogenesis of pelvic serous carcinoma (summarized in Table 4 ).
This study addressed tumors classified as serous carcinoma, and did not exclude any of the 3 possible extrauterine sources. It is clear from Table 2 that the distal tube cannot be implicated in the pathogenesis of all pelvic serous carcinomas, despite the intriguing prior reports in the BRCA+ women. What is apparent from this study and others, however, is the following: (1) Tumors that are readily classified as primary tubal neoplasms usually involve the fimbria, contain TIC (by definition) and predominate in the fallopian tube with variable involvement of the adjacent peritoneal surfaces. 8, 13, 18 (2) Tumors suspected on gross exam as primary peritoneal carcinomas often exhibit TIC or involvement of the endosalpinx (Fig. 2) . (3) Tumors classified as primary ovarian serous carcinomas often involve the endosalpinx and many of these contain TIC. Of 42 cases classified as primary ovarian serous carcinomas in this study, 30 (71%) involved the endosalpinx and 20 (48%) contained TIC. Importantly, 29 of the 30 cases involving the endosalpinx and all of 20 cases with TIC exhibited both superficial and parenchymal ovarian involvement with variable cyst formation (Figs. 3, 4) . (4) When the inner lining of the tube is not involved, a plausible preexisting ovarian condition (endometriotic cyst or cystadenoma) or a growth pattern (dominant ovarian mass) supports an origin from the ovary in most cases (Table 2) . (5) Less frequently, TIC can be identified in the region of the ovary, arising in association with benign salpingeal-type epithelium within tubal adhesions or endosalpingiosis (Fig. 5) .
A diagnosis of intraepithelial carcinoma in the salpingeal mucosa must be made with attention to at least 3 pitfalls. The first is misdiagnosis of benign epithelial changes as carcinoma. Intraepithelial serous carcinoma is a relatively new concept. However, the criteria for this entity are applied in the endometrium and recent studies of TIC have revealed an identical morphology, which is strongly p53 and MIB-1 positive. 8, 18 The second pitfall is the possibility that ''intraepithelial carcinoma'' is actually an implant from a remote tumor. At this point in our understanding of TIC, it would be premature to assume that all TICs are primary tubal neoplasms. However, 2 observations support the concept that TIC originates in the fallopian tube mucosa. The first is that the tubal mucosa appears resistant to direct mucosal implantation. The salpingeal mucosa is rarely the site for implants from endometrioid, mucinous or borderline serous neoplasms. Metastatic mucinous tumors likewise frequently involve the ovarian or tubal serosal surfaces, yet spare the mucosa. Although it is conceivable that serous carcinomas of the ovary would implant on the fimbrial mucosa, they typically involve the serosal aspect. The second is that TIC is recognized as the earliest manifestation of pelvic serous carcinoma in both BRCA+ and sporadic tubal carcinomas (Figs. 1A, B) . 9, 11 Because TIC is often the only neoplasm present in these cases, we assume that it is an early manifestation of serous carcinoma. In this study, other potential sources, such as endometrium, were also considered, because endometrial involvement was seen in 4 cases. However, in all 4, the distribution of the implants (endometrial surface only without intraepithelial carcinoma, multifocal small plaques of advanced carcinoma, and submucosal lymphatic involvement) was characteristic of a drop metastasis rather than a primary serous neoplasm.
The third pitfall is that TIC, although a primary tubal neoplasm, might not be genetically related to the ovarian or peritoneal carcinoma in question and represents a second primary. This was addressed by analysis of both TIC and ovarian carcinomas for p53 mutations, which confirmed a genetic link between the 2 tumors in 5 of 5 cases analyzed (Table 3) . Although the numbers are small, the findings are consistent with earlier studies suggesting that most, but not all, ovarian and peritoneal serous tumors have a common (monoclonal or unifocal) genetic basis. On one hand, the identical nature of mutations found in different tumor sites is consistent with prior observations in ovarian serous carcinoma. 29 Conversely, the presence of disparate mutations in 2 different sites of TIC in one case supports a multiclonal origin for some peritoneal serous carcinomas as observed in another report (Table 3) . 24 Taking the above into account, a provisional (and testable) model of pelvic serous carcinogenesis can be constructed, which is illustrated in Figure 6 . The first pathway consists of a traditionally accepted route, in which mullerian epithelium is established in the ovary or peritoneal surface in the form of endo salpingiosis (including adhesions), mullerian metaplasia or endometriosis. 25, 33 The mullerian epithelium itself, or an intervening benign ovarian neoplasm arising in this epithelium, would serve as the source for the serous carcinoma (Fig. 6, left pathway) .
14 This scenario would explain several of the cases in this report that were not associated with TIC ( Table 2) .
The second proposed pathway entails malignant transformation of the distal fallopian tube mucosa, initiating as TIC within a preexisting normal-appearing but probably genetically altered epithelium. In this setting, subclones of TIC would evolve by invading underlying stroma, and either the intraepithelial or the invasive tumor would exfoliate to the ovarian and/or peritoneal surfaces, or both, as suggested by the cases illustrated in this report. Instances in which remote metastases were more extensive than the tumor of origin (as shown in Fig. 2D ) are common and have been reported in preinvasive serous carcinomas of the endometrium. 27 Like their counterparts in the endometrium, TICs apparently have the capacity to spread beyond the In this scenario, the proximity of the distal fallopian tube to the ovarian surface or peritoneal cavity facilitates early spread of more aggressive tumor clones, which grow at a greater rate in these remote sites. This above model permits the introduction of at least 4 variables that may be involved in the pathogenesis of pelvic cancer including: (1) site of origin, which may be a function of whether the patient is prone to ovarian surface mullerian metaplasia or transfer of tubal epithelium to the ovarian surface via endosalpingiosis or adhesions; (2) release of potentially carcinogenic factors during ovulation, which would impact on both the ovarian surface and distal fallopian tube epithelium 19 ; (3) timing of neoplastic transformation, which is accelerated in women with heritable mutations in the BRCA genes; and (4) tumor initiation and progression. Multiple sites of TIC (or a similar lesion occurring on the ovarian surface epithelium) conceivably could give rise to multiclonal tumors. Biologic properties of a tumor arising from the distal fallopian tube (or ovarian surface epithelium) could determine whether it remained in its original site (and classified as a primary tubal or ovarian carcinoma), preferentially grew on the peritoneal surfaces (and classified as a peritoneal carcinoma) or invaded the underlying parenchyma of the ovaries (and classified as an ovarian primary). Importantly, none of these scenarios precludes an origin from either the ovarian surface epithelium or the distal fallopian tube. Currently, the incidence of fallopian tube carcinoma is estimated to be approximately one-fiftieth (0.3 vs. 15 per 100,000) that of ovarian carcinoma, in the United States. 22, 23 Some of this disparity is due to the multiple types of ovarian carcinoma that do not share a common pathogenesis with the tube. However, based on this study, TIC is not a rare event in pelvic serous cancer. A critical assessment of TIC as an early form of primary tubal malignancy combined with more thorough tubal examination in cases of pelvic serous carcinoma is needed to precisely determine the frequency of this disease and its potential impact on serous cancer incidence.
In addition to evidence that TIC may be an important initiator of pelvic and ovarian cancer, is support for a precursor pathway in the distal fallopian tube. 16 In a recent study, epithelial changes have been identified in benign appearing mucosa that possess several attributes of TIC, including p53 immunopositivity, p53 mutations, fimbrial location, evidence of DNA damage, and a specific cell target (the secretory cell) that has been implicated as the source of tubal serous carcinoma. 17 These genetic lesions, termed ''p53 signatures,'' have many of the attributes of TIC although lacking the marked atypia and proliferative activity of the latter. 17 The presence of DNA damage in p53 signatures is particularly interesting, in light of experimental data implicating ovulation as a source of oxidative injury. 19 The exact proportion of cases of ovarian or peritoneal serous carcinoma that can be attributed to the distal fallopian tube remains to be determined by larger studies. Nevertheless, TIC merits close attention as a candidate source for these tumors and must be incorporated into future discussions of the classification of tumors currently designated as primary peritoneal and ovarian serous carcinomas. The SEE-FIM or a similar protocol should be employed to provide a precise estimate of fimbrial involvement. Similar efforts should eventually clarify the role of the fimbria in pelvic serous carcinogenesis, tumor classification and possibly, serous cancer prevention.
